As Chief Operating Officer & Senior Vice President of Compliance for ADMA Biologics, Ms. Kestenberg is responsible for ensuring Company activities comply with regulations and the expectations of governing bodies as well as oversees company-wide project planning, project management, and oversight for clinical programs and operations.
Along with the executive team, Kaitlin was instrumental in conducting due diligence on the Biotest Therapy Business Unit acquisition as well as playing an integral role in integration of corporate operations, compliance and FDA-regulated functions. She led significant portions of ADMA’s compliance and quality assurance overhaul, worked on teams developing novel regulatory affairs strategies, led the team responsible for drafting the ASCENIV™ BLA and other significant regulatory submissions and is credited with preparing the company for a successful FDA inspection post acquisition. Ms. Kestenberg has participated in and led numerous FDA interactions for ADMA and has attended multiple face-to-face FDA meetings during her tenure.
Ms. Kestenberg joined ADMA Biologics as Clinical Research Manager in 2012 and has received multiple promotions and positions of increasing responsibility. Prior to joining ADMA, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics and Merck.
Ms. Kestenberg has over 12 years of project management and clinical operations experience including successful Phase 3 clinical trials and subsequent regulatory filings. She was responsible for all operational aspects and site management and oversite of ADMA’s Phase 3 clinical program used as the basis for ADMA’s drug approval for ASCENIV™. She has led cross-functional teams across numerous therapeutic areas including immunology, infectious diseases, multiple sclerosis, congestive heart failure, acute spinal cord injury, HIV, hepatitis Clostridioides difficile, and diabetes.
She holds a BA from the State University of New York at Albany and an MSJ from Seton Hall University.
What is Kaitlin M. Kestenberg-Messina's net worth?
The estimated net worth of Kaitlin M. Kestenberg-Messina is at least $8.94 million as of August 30th, 2024. Kestenberg-Messina owns 449,088 shares of ADMA Biologics stock worth more than $8,936,851 as of April 1st. This net worth approximation does not reflect any other investments that Kestenberg-Messina may own. Learn More about Kaitlin M. Kestenberg-Messina's net worth.
How do I contact Kaitlin M. Kestenberg-Messina?
Has Kaitlin M. Kestenberg-Messina been buying or selling shares of ADMA Biologics?
Kaitlin M. Kestenberg-Messina has not been actively trading shares of ADMA Biologics within the last three months. Most recently, Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a transaction totalling $408,135.00. Following the completion of the sale, the chief operating officer now directly owns 449,088 shares of the company's stock, valued at $7,589,587.20. Learn More on Kaitlin M. Kestenberg-Messina's trading history.
Who are ADMA Biologics' active insiders?
ADMA Biologics' insider roster includes Steve Elms (Director), Bryant Fong (Director), Adam Grossman (Co-Founder, President, CEO & Director), Jerrold Grossman (Director), Lawrence Guiheen (Director), Kaitlin Kestenberg-Messina (COO), Young Kwon (Director), Brian Lenz (CFO), and Brad Tade (CFO & Treasurer). Learn More on ADMA Biologics' active insiders.
Are insiders buying or selling shares of ADMA Biologics?
During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 581,900 shares worth more than $9,613,370.88. The most recent insider tranaction occured on November, 22nd when CFO Brad L Tade sold 15,000 shares worth more than $317,250.00. Insiders at ADMA Biologics own 3.7% of the company.
Learn More about insider trades at ADMA Biologics. Information on this page was last updated on 11/22/2024.
